Results 21 to 30 of about 1,156,270 (203)

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Neuropsychiatric Disease and Treatment, 2008
Kenou van RijckevorselReference Centre of Refractory Epilepsy, Cliniques Universitaires St Luc, Université Catholique de Louvain, Brussels, BelgiumAbstract: Lennox-Gastaut syndrome (LGS) is a rare, age-related syndrome, characterized by ...
Kenou van Rijckevorsel
doaj   +1 more source

Rufinamide in patients with Lennox-Gastaut syndrome

Nursing: Research and Reviews, 2016
Peggy O Clark,1 Patricia A Gibson2 1Cincinnati Children’s Hospital Medical Center, The University of Cincinnati College of Medicine, Cincinnati, OH, 2Epilepsy Information Service, Wake Forest University School of Medicine, Winston-Salem, NC, USA ...
Clark PO, Gibson PA
doaj   +1 more source

Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide

Neuropsychiatric Disease and Treatment, 2010
Jessica Gresham1, Lea S Eiland2,3, Allison M Chung2,41Auburn University, Harrison School of Pharmacy (AUHSOP), 2Department of Pharmacy Practice, AUHSOP, 3University of Alabama, School of Medicine, Huntsville Regional Medical Campus, 4University of South ...
Jessica Gresham, Lea S Eiland, Allison M Chung   +2 more
doaj   +2 more sources

Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions

Neuropsychiatric Disease and Treatment, 2017
Adam P Ostendorf,1 Yu-Tze Ng2 1Department of Pediatrics, Neurology Section, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH, 2Department of Pediatrics, Baylor College of Medicine, The Children’s Hospital of San ...
Ostendorf AP, Ng YT
doaj   +1 more source

Targeting thalamocortical circuits for closed-loop stimulation in Lennox-Gastaut syndrome. [PDF]

Brain Commun
This paper outlines the therapeutic rationale and neurosurgical targeting technique for bilateral, closed-loop, thalamocortical stimulation in Lennox-Gastaut syndrome, a severe form of childhood-onset epilepsy.
Warren AEL, Butson CR, Hook MP, Dalic LJ, Archer JS, Macdonald-Laurs E, Schaper FLWVJ, Hart LA, Singh H, Johnson L, Bullinger KL, Gross RE, Morrell MJ, Rolston JD.   +13 more
europepmc   +2 more sources

Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children [PDF]

International Neurourology Journal, 2021
Epileptic encephalopathy (EE) is a devastating pediatric disease that features medically resistant seizures, which can contribute to global developmental delays.
Ja Un Moon, Kyung-Ok Cho
doaj   +1 more source

Expanding the electroclinical spectrum of TANC2-related disorders: Lennox-Gastaut syndrome and related developmental epileptic phenotypes. [PDF]

Epilepsia Open
Abstract Objective Neurodevelopmental disorders (NDDs) and epilepsy are often associated. Increasing evidence highlights a pivotal role for pathogenic variants in genes encoding synaptic scaffolding proteins. Within this group, TANC2 has recently been implicated in intellectual developmental disorder with autistic features and language delay, with or ...
Perilli L, Stipa C, Villano G, Licchetta L, Strothmann L, Jauss RT, Kluger GJ, Minardi R, NETRE consortium, Gobbi G, Grosso S, Bisulli F, Striano P.   +12 more
europepmc   +2 more sources

The surgical treatment improving at Lennox–Gastaut syndrome

Ukrainian Neurosurgical Journal, 2007
The modern sights of Lennox–Gastaut syndrome management are given. The surgical methods, used in Lennox–Gastaut syndrome treatment are described.
A. O. Laponogov, V. I. Tsymbalyuk, K. R. Kostyuk   +2 more
doaj   +1 more source

Lennox-Gastaut and Schizophrenia: Comorbidity or complication?

European Psychiatry, 2022
Introduction Lennox-Gastaut syndrome (LGS) belongs to the group of severe childhood epileptic encephalopathies and represents 1 to 2% of all childhood epilepsies.It is characterized by the occurrence of generalized epileptic seizures, characterized by a
Z. Bencharfa, Y. Amara, L. Tbatou, S. Belbachir, A. Ouanass   +4 more
doaj   +1 more source

Changes in effectiveness and safety in patients with Lennox-Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open-label extension study. [PDF]

Epilepsia Open
This graphical abstract provides an overview of the content from this post hoc analysis describing the trajectories of fenfluramine effectiveness and safety, along with dose changes over time, in patients with Lennox‐Gastaut syndrome. Abstract In the phase 3 randomized controlled trial (RCT; NCT03355209) of fenfluramine in Lennox–Gastaut syndrome (LGS),
Nabbout R, Devinsky O, Lagae L, Scheffer IE, Guerrini R, Sullivan J, Gil-Nagel A, Zuberi SM, Riney K, Healy P, Abraham J, Roper RZ, Langlois M, Lothe A, Knupp KG.   +14 more
europepmc   +2 more sources